ArticleJournal of gastric cancer2026
Clinical Implications of Histologic Heterogeneity in Endoscopic Submucosal Dissection Specimens for Differentiated-Type Early Gastric Cancer.
Article in Journal of gastric cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe clinical implications of histologic heterogeneity, defined as differentiated-type early gastric cancer (EGC) containing undifferentiated components, in endoscopic submucosal dissection (ESD) specimens remain unclear. We investigated the association of histologic heterogeneity and biopsy-detected poorly differentiated components with lymph node metastasis in differentiated-type EGC. MATERIALS AND
methodsThis retrospective study included 858 patients who underwent gastrectomy after ESD for differentiated-type EGC. Histologic heterogeneity in ESD specimens and its association with clinicopathological features, including lymph node metastasis, were analyzed. In addition, 88 pre-treatment biopsy specimens were reviewed for the presence of poorly differentiated components.
resultsHistologic heterogeneity was identified in 252 (29.4%) patients, and lymph node metastasis was detected in 46 (5.4%) patients. Histologic heterogeneity was significantly associated with higher frequencies of lymphatic invasion (73.4% vs. 50.8%, P<0.001) and lymph node metastasis (8.3% vs. 4.1%, P=0.013). Among patients with available biopsy specimens, poorly differentiated components identified on biopsy were observed only in lesions with histologic heterogeneity in ESD specimens and were associated with a higher frequency of lymph node metastasis (37.5% vs. 2.5%, P=0.005).
conclusionsHistologic heterogeneity in ESD specimens was associated with adverse pathological features, including lymphatic invasion and lymph node metastasis. These findings support the detailed documentation of histologic heterogeneity in ESD pathology reports and minor poorly differentiated components in biopsy specimens to assist in risk stratification and individualized treatment planning for differentiated-type EGC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.